Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma

Detalles Bibliográficos
Autores principales: Dührsen, Ulrich, Tometten, Mareike, Kroschinsky, Frank, Ganser, Arnold, Ibach, Stefan, Bertram, Stefanie, Hüttmann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129096/
https://www.ncbi.nlm.nih.gov/pubmed/34001867
http://dx.doi.org/10.1038/s41408-021-00485-5
_version_ 1783694238931746816
author Dührsen, Ulrich
Tometten, Mareike
Kroschinsky, Frank
Ganser, Arnold
Ibach, Stefan
Bertram, Stefanie
Hüttmann, Andreas
author_facet Dührsen, Ulrich
Tometten, Mareike
Kroschinsky, Frank
Ganser, Arnold
Ibach, Stefan
Bertram, Stefanie
Hüttmann, Andreas
author_sort Dührsen, Ulrich
collection PubMed
description
format Online
Article
Text
id pubmed-8129096
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81290962021-05-27 Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma Dührsen, Ulrich Tometten, Mareike Kroschinsky, Frank Ganser, Arnold Ibach, Stefan Bertram, Stefanie Hüttmann, Andreas Blood Cancer J Correspondence Nature Publishing Group UK 2021-05-17 /pmc/articles/PMC8129096/ /pubmed/34001867 http://dx.doi.org/10.1038/s41408-021-00485-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Dührsen, Ulrich
Tometten, Mareike
Kroschinsky, Frank
Ganser, Arnold
Ibach, Stefan
Bertram, Stefanie
Hüttmann, Andreas
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title_full Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title_fullStr Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title_full_unstemmed Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title_short Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
title_sort phase i/ii trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (lemlar) in relapsed or refractory diffuse large b cell lymphoma
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129096/
https://www.ncbi.nlm.nih.gov/pubmed/34001867
http://dx.doi.org/10.1038/s41408-021-00485-5
work_keys_str_mv AT duhrsenulrich phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT tomettenmareike phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT kroschinskyfrank phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT ganserarnold phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT ibachstefan phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT bertramstefanie phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma
AT huttmannandreas phaseiiitrialoflenalidomidemethotrexateleucovorincytarabineandrituximablemlarinrelapsedorrefractorydiffuselargebcelllymphoma

Ejemplares similares